A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein
- 11 March 2022
- Vol. 40 (15) , 2299-2310
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activationJournal of Infection, 2012
- Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2Journal of Virology, 2010
- Cross-Reacting Antibodies Enhance Dengue Virus Infection in HumansScience, 2010
- Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibodyVirology, 2009
- Deletion of the C-Terminal Region of Dengue Virus Nonstructural Protein 1 (NS1) Abolishes Anti-NS1-Mediated Platelet Dysfunction and Bleeding TendencyThe Journal of Immunology, 2009
- Proteomic Analysis of Endothelial Cell Autoantigens Recognized by Anti-Dengue Virus Nonstructural Protein 1 AntibodiesExperimental Biology and Medicine, 2009
- C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular MimicryAmerican Journal of Infectious Diseases, 2008
- Antibodies from dengue patient sera cross‐react with endothelial cells and induce damageJournal of Medical Virology, 2002
- High Circulating Levels of the Dengue Virus Nonstructural Protein NS1 Early in Dengue Illness Correlate with the Development of Dengue Hemorrhagic FeverThe Journal of Infectious Diseases, 2002
- Generation of IgM anti-platelet autoantibody in dengue patientsJournal of Medical Virology, 2001